HC Wainwright Lowers Neoleukin Therapeutics (NASDAQ:NLTX) Price Target to $6.00

Neoleukin Therapeutics (NASDAQ:NLTXGet Rating) had its price objective decreased by HC Wainwright from $22.00 to $6.00 in a report issued on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.

A number of other analysts also recently weighed in on the stock. Piper Sandler decreased their price target on shares of Neoleukin Therapeutics from $25.00 to $6.00 in a research report on Friday, May 27th. Canaccord Genuity Group reissued a buy rating and set a $10.00 price target on shares of Neoleukin Therapeutics in a research report on Wednesday, July 6th.

Neoleukin Therapeutics Trading Down 1.8 %

NLTX stock opened at $1.07 on Monday. Neoleukin Therapeutics has a twelve month low of $0.80 and a twelve month high of $8.48. The company has a market capitalization of $45.56 million, a P/E ratio of -0.95 and a beta of 1.08. The firm has a 50 day simple moving average of $1.08 and a 200-day simple moving average of $1.33.

Hedge Funds Weigh In On Neoleukin Therapeutics

Large investors have recently added to or reduced their stakes in the company. Adviser Investments LLC lifted its stake in Neoleukin Therapeutics by 347.6% during the first quarter. Adviser Investments LLC now owns 46,817 shares of the company’s stock worth $88,000 after purchasing an additional 36,357 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in Neoleukin Therapeutics by 1.1% during the fourth quarter. Point72 Asset Management L.P. now owns 1,010,790 shares of the company’s stock worth $4,872,000 after purchasing an additional 10,790 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Neoleukin Therapeutics by 73.6% in the fourth quarter. GSA Capital Partners LLP now owns 130,899 shares of the company’s stock valued at $631,000 after buying an additional 55,480 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Neoleukin Therapeutics in the fourth quarter valued at $112,000. Finally, Walleye Capital LLC bought a new stake in Neoleukin Therapeutics in the first quarter valued at $27,000. 49.19% of the stock is currently owned by institutional investors.

Neoleukin Therapeutics Company Profile

(Get Rating)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Further Reading

The Fly logo

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.